The chief strategist at Piper Jaffray released his report for March. It details how the second and third quarters typically behave in the mid-term years after a solid first quarter. Here are…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Thursday, February 13, 2014. They include Angie's List, Itron, NVIDIA, Regeneron and Sempra Energy.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, February 12, 2014. They include Amazon, Control4, Ocwen Financial, Sprint and Veeco Instruments.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, January 15.
Baird offers an eclectic and interesting list for investors. A top regional firm, it tends to dig a little deeper, looking for ideas with not only growth potential, but catalysts. The usual…
courtesy of Apple Inc.Like most firms that we cover on Wall Street, Piper Jaffray has updated its top names to buy for 2014, and the firm has an extensive market commentary to…
ThinkstockCredit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance up 73%. Given…
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to…
ThinkstockThe UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed significantly year to date, hedge…
ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what…
ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top companies…
Jon OggNow that stocks have pulled back and interest rates have risen, investors are looking for more guidance on which stocks they should still buy and which stocks they should sell or…
Stock splits have long been cheered by the investing community. After all, this gives retail investors the chance to get back in a stock at a more reasonable share price. You may…
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company has now…
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise is the difference between…
